Business Description
Waverley Pharma Inc
NAICS : 325412
SIC : 3741
ISIN : CA94357L1058
Compare
Compare
Traded in other countries / regions
WAVE.Canada5GZ.Germany IPO Date
2017-04-27Description
Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics that focuses on oncology. The company products pipeline includes Bortezomib, Pemetrexed, Capecitabine, and Temozolomide, among others.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.08 | |||||
| Equity-to-Asset | -1.13 | |||||
| Debt-to-Equity | -1.47 | |||||
| Debt-to-EBITDA | -1.63 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -16.56 | |||||
| Beneish M-Score | -8.2 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -31.6 | |||||
| 3-Year EBITDA Growth Rate | -4.9 | |||||
| 3-Year EPS without NRI Growth Rate | -32 | |||||
| 3-Year FCF Growth Rate | -39.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.17 | |||||
| 9-Day RSI | 35.82 | |||||
| 14-Day RSI | 38.56 | |||||
| 6-1 Month Momentum % | -57.14 | |||||
| 12-1 Month Momentum % | -40 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.13 | |||||
| Quick Ratio | 0.09 | |||||
| Cash Ratio | 0.07 | |||||
| Days Inventory | 117.58 | |||||
| Days Sales Outstanding | 116.2 | |||||
| Days Payable | 818.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -224.85 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 20.71 | |||||
| Operating Margin % | -573.37 | |||||
| Net Margin % | -905.33 | |||||
| FCF Margin % | -310.36 | |||||
| ROA % | -217.95 | |||||
| ROIC % | -68.66 | |||||
| ROC (Joel Greenblatt) % | -766.54 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.67 | |||||
| EV-to-EBIT | -1.67 | |||||
| EV-to-EBITDA | -1.8 | |||||
| EV-to-Revenue | 9.65 | |||||
| EV-to-FCF | -3.11 | |||||
| Earnings Yield (Greenblatt) % | -59.88 | |||||
| FCF Yield % | -194.26 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Waverley Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | 0.338 | ||
| EPS (TTM) (C$) | -0.055 | ||
| Beta | 1.15 | ||
| Volatility % | 94.06 | ||
| 14-Day RSI | 38.56 | ||
| 14-Day ATR (C$) | 0.001205 | ||
| 20-Day SMA (C$) | 0.01425 | ||
| 12-1 Month Momentum % | -40 | ||
| 52-Week Range (C$) | 0.01 - 0.035 | ||
| Shares Outstanding (Mil) | 54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Waverley Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Waverley Pharma Inc Stock Events
| Event | Date | Price(C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Waverley Pharma Inc Frequently Asked Questions
What is Waverley Pharma Inc(TSXV:WAVE)'s stock price today?
The current price of TSXV:WAVE is C$0.01. The 52 week high of TSXV:WAVE is C$0.04 and 52 week low is C$0.01.
When is next earnings date of Waverley Pharma Inc(TSXV:WAVE)?
The next earnings date of Waverley Pharma Inc(TSXV:WAVE) is .
Does Waverley Pharma Inc(TSXV:WAVE) pay dividends? If so, how much?
Waverley Pharma Inc(TSXV:WAVE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers